Lumican and tumor therapy resistance / 国际肿瘤学杂志
Journal of International Oncology
;
(12): 87-90, 2023.
Artículo
en Chino
| WPRIM
| ID: wpr-989526
ABSTRACT
Lumican is a member of the small leucine-rich proteoglycan family, which is involved in cell processes related to tumorigenesis and development, such as epithelial-mesenchymal transition, cell proliferation, migration, invasion and adhesion. The expression of Lumican in different tumors is positively or negatively correlated with tumor progression, and can be used as a reference for tumor prognosis and efficacy evaluation. Further study of the correlation and potential mechanism between Lumican and tumor therapy resistance can provide new ideas for predicting clinical therapeutic efficacy.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Journal of International Oncology
Año:
2023
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS